Search Results - "Shukhov, O A"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review by Gurianova, M A, Chelysheva, E Y, Shukhov, O A, Turkina, A G

    Published in Terapevtic̆eskii arhiv (01-09-2020)
    “…Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera by Sokolova, M A, Turkina, A G, Melikian, A L, Sudarikov, A B, Treglazova, S A, Shukhov, O A, Gemdzhian, E G, Abdullaev, A О, Kovrigina, A M, Misyurin, A V, Pliskunova, Yu V, Ivanova, V L, Moiseeva, T N

    Published in Terapevtic̆eskii arhiv (01-01-2016)
    “…To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). A total of 61 patients (41…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid Leukemia before Discontinuation of Tyrosine Kinase Inhibitors by Petinati, N. A., Petrova, A. N., Chelysheva, E. Yu, Shukhov, O. A., Bykova, A. V., Nemchenko, I. S., Sats, N. V., Turkina, A. G., Drize, N. I.

    “…We analyzed changes in multipotent mesenchymal stromal cells of patients with chronic myeloid leukemia before discontinuation of tyrosine kinase inhibitors…”
    Get full text
    Journal Article
  7. 7

    Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia by Chelysheva, Ekaterina Yu, Petrova, Anna N., Shukhov, Oleg A., Bykova, Anastasiia V., Nemchenko, Irina S., Gurianova, Margarita A., Tsyba, Nikolay N., Turkina, Anna G.

    Published in Terapevtic̆eskii arhiv (12-08-2022)
    “…Background. Withdrawal syndrome (WS) a musculoskeletal pain after discontinuation of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia…”
    Get full text
    Journal Article
  8. 8
  9. 9